Sheila Jane Zanoria, MD
Pulmonary Disease · Waterbury, CTNPI 1508182965
Payments from drug & device makers
Across 488 payments — averaging $20.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$3K
- AstraZeneca$2K
- Sanofi$816
- Boehringer Ingelheim$810
- Regeneron Healthcare Solutions, Inc.$690
- Takeda Pharmaceuticals U.S.A., Inc.$571
- plus $3K from 31 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 150 | $2,567 |
| AstraZeneca(2 entities) | 91 | $1,818 |
| Sanofi | 28 | $816 |
| Boehringer Ingelheim | 39 | $810 |
| Regeneron Healthcare Solutions, Inc. | 31 | $690 |
| Takeda Pharmaceuticals U.S.A., Inc. | 22 | $571 |
| Amgen | 25 | $504 |
| Verona Pharma, Inc. | 8 | $320 |
| Novartis | 16 | $302 |
| Mylan Specialty L.p. | 13 | $239 |
| Inspire Medical Systems, Inc. | 2 | $130 |
| Optinose US, Inc. | 4 | $113 |
| Viatris Specialty LLC | 5 | $100 |
| Genentech USA, Inc. | 5 | $96 |
| Electromed, Inc. | 5 | $93 |
| Philips North America LLC | 4 | $71 |
| Paratek Pharmaceuticals, Inc. | 4 | $69 |
| Actelion Pharmaceuticals US, Inc. | 2 | $64 |
| Merck | 3 | $60 |
| Grifols USA, LLC | 2 | $58 |
| Pulmonx Corporation | 3 | $55 |
| Covis Pharma GmbH | 3 | $54 |
| Vifor Pharma, Inc. | 2 | $49 |
| Johnson & Johnson | 3 | $47 |
| Baxter Healthcare | 2 | $43 |
| Seqirus USA Inc | 2 | $39 |
| Advanced Respiratory, Inc | 2 | $39 |
| AbbVie | 2 | $35 |
| Insmed, Inc. | 2 | $32 |
| E.r. Squibb & Sons, L.L.C. | 1 | $31 |
| CSL Behring | 1 | $27 |
| Mallinckrodt Hospital Products Inc. | 1 | $21 |
| Pfizer | 1 | $19 |
| Phadia US Inc. | 1 | $18 |
| Lilly USA, LLC | 1 | $14 |
| Sunovion Pharmaceuticals Inc. | 1 | $13 |
| Watermark Medical, Inc. | 1 | $13 |
How this compares
$10,040 in reported general payments places this provider in the 75th percentile of 255 pulmonary disease providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Waterbury
- Jameel UddeenWaterbury$18K
- Geoffrey ChuppNew Haven$3.1M
- Jonathan KoffNew Haven$1.1M
- Naftali KaminskiNew Haven$1M
- Danielle Antin-OzerkisNew Haven$1M
- Mircea BadaraNew Britain$1M
- Mridu GulatiNew Haven$536K
- Phillip JosephNew Haven$488K
- Tapas BandyopadhyayWest Hartford$483K
- Raj ParikhHartford$419K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.